Researcher

Tony Wyss-Coray

Last updated Sun May 17 2026 00:00:00 GMT+0000 (Coordinated Universal Time)· 2 min read

Background

Tony Wyss-Coray is Professor of Neurology at Stanford University and director of the Phil and Penny Knight Initiative for Brain Resilience. He trained in immunology at the University of Bern then transitioned into neuroscience and aging research, becoming one of the most cited voices on systemic factors in brain aging.

Key contributions

Heterochronic parabiosis and young plasma

Re-launched modern interest in heterochronic parabiosis — surgically joining the circulations of young and old mice — and plasma-transfer experiments showing improvements in cognition, hippocampal neurogenesis, and synaptic plasticity in old mice. The 2014 Villeda et al. Nature Medicine paper is among the foundational works.

Candidate "young factors"

Identified specific candidate factors in young plasma that may drive the rejuvenation effects:

GDF11 — initially celebrated, later controversial after replication issues.
TIMP2 (tissue inhibitor of metalloproteinases-2) — better replicated; signals through specific pathways to support hippocampal function.
Several additional candidates in ongoing work.

Organ-aging proteomics

A series of large plasma-proteomic studies (Lehallier, Oh, and others) showed that different organs within the same person have different "biological ages" detectable from plasma protein signatures. This heterogeneity may be the most consequential shift in biomarker thinking of the past decade — aging is not a single number per person.

Translational

Helped launch first young-plasma human trials in Alzheimer’s through Alkahest (acquired by Grifols 2020, leading to the AMBAR-style plasma-exchange programmes). More recently a co-founder of Vesalius Therapeutics targeting age-related neurodegeneration.

Influence

Organ-aging changed biomarker thinking

The plasma-proteomic finding that different organs within one person age at different rates fundamentally reshapes how biological-age measurement is approached. A single epigenetic-clock value per person may average over substantial inter-organ heterogeneity. Future clinical applications will likely report organ-specific aging scores.

Affiliations & disclosures

Stanford. Co-founder of Vesalius Therapeutics and prior co-founder of Alkahest (now part of Grifols’ plasma-research arm). Financial disclosures appear with publications.

References

Villeda, S. A. et al. Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice. Nat. Med. 20, 659–663 (2014).